Abbvie Inc.

Abbott Laboratories Corporation

Abbvie Deutschland Gmbh and Co Kg

Abbvie Bahamas Limited

Abbvie Ireland Unlimited Company

Tariq Ghayur

Chengbin Wu

Chung-Ming Hsieh

Dominic J Ambrosi

Jijie Gu

Peter C Isakson

Jochen G Salfeld

Carrie Goodreau

Junjian Liu

Achim Moeller

Richard W Dixon

Bernhard K Mueller

Boris Labkovsky

Mario Mezler

Martin Schmidt

Nicole Teusch

Reinhold Mueller

Eve H Barlow

Maria Harris

Axel Meyer

Larry L Green

Andrew J Souers

Xiao-Chi Jia

Steven Elmore

Jaspal Singh Kang

Zehra Kaymakcalan

John Stephen Babcook

Lorenzo Benatuil

George Avgerinos

Jeffrey W Voss

Rajesh Vasant Kamath

Michael McPherson

James Wieler

Albert Collinson

Stuart J Perper

Brad Hedberg

Sonal Saluja

Lichun Wang

Ravi Chari

Jieyi Wang

Randy Bell

Susan E Brophy

Edward B Reilly

Feng Dong

Susan Elizabeth Morgan-Lappe

Gillian A Kingsbury

Yingchun Li

Anca Clabbers

Hamish John Allen

Margaret Hugunin

Lisa Maria Olson

Andrew C Phillips

Hua Ying

Carolyn A Cuff

Philip D Bardwell

Marie P Honore

Alfred Hahn

Sharmila Manoj

Li Chun Wang

Lucia Eaton

Sahana Bose

Chung-ming Hsieh

Diana Bowley

Matthew Rieser

Georgeen Gaza-Bulseco

Pratibha Mishra

Subramanya Hegde

Sudha Krishnan

Suzanne M Norvell

Junian Liu

The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind to the Nogo-66 receptor. Specifically, these antibodies have the ability to inhibit the binding of the natural ligand of the Nogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or portions thereof of the invention are useful for detecting NgR and for inhibiting NgR activity, for example in a human suffering from a disorder in which NgR or Nogo-66 activity is detrimental.

Neutralizing monoclonal antibodies against the Nogo-66 receptor (NgR) and uses thereof

This invention pertains to methods of treating systemic lupus erythematosus and Sjogren's Syndrome with compounds that selectively inhibit the activity of Bcl-2 anti-apoptotic proteins. Specifically, the current invention is directed to treatment with compounds that selectively inhibit the activity of Bcl-2 proteins, with a lesser affinity for inhibiting the activity of other BCL-2 family proteins, including Bcl-X.

Methods of treatment using selective Bcl-2 inhibitors

Engineered monovalent binding proteins that bind to one or more ligands (such as an antigen) via one binding domain are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.

Monovalent binding proteins

Binding proteins that bind one or more of VEGF, PDGF and/or their receptors, including antibodies, CDR-grafted antibodies, humanized antibodies, binding fragments, fusion proteins, and bispecific or multispecific proteins thereof are disclosed. Also disclosed are methods of making and using the binding proteins.

Antibodies against platelet-derived growth factor (PDGF)

Provided are glycoengineered populations of Fc domain-containing binding proteins with a reduced anti-drug immune response (ADA). Also provided are methods of treating disease using such compositions, and methods and host for making such compositions.

Glycoengineered binding protein compositions

Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided.

Dual variable domain immunoglobulins and uses thereof

Proteins that bind IL-1&#x3b1; and IL-1&#x3b2; are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1&#x3b1; and IL-1&#x3b2; in cells, tissues, samples, and compositions.

IL-1 binding proteins

This invention pertains to methods of treating systemic lupus erythematosus and Sjogren's Syndrome with compounds that selectively inhibit the activity of Bcl-2 anti-apoptotic proteins. Specifically, the current invention is directed to treatment with compounds that selectively inhibit the activity of Bcl-2 proteins, with a lesser affinity for inhibiting the activity of other BCL-2 family proteins, including Bcl-x.

Isolated binding proteins, e.g., antibodies or antigen binding portions thereof, which bind to tumor necrosis factor-alpha (TNF-&#x3b1;), e.g., human TNF-&#x3b1;, and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies.

TNF-&#x3b1; binding proteins

Engineered multivalent and multispecific binding proteins that bind IL-13 and/or IL-17 are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.

Dual specific binding proteins directed against IL-13 and IL-17

Growing community of inventors

Holliston, MA, United States of America

Tariq Ghayur